| |
SUVmax-T n(%)
|
SUVmax-N n(%)
|
SUVmax-M n(%)
|
EBV DNA n(%)
|
|---|
|
Characteristic
| | |
P value
| | |
P value
| | |
P value
| | |
P value
|
|---|
|
Total
|
175
|
78
| |
104
|
149
| |
77
|
176
| |
95
|
158
| |
|
Gender
|
|
Male
|
148(84.6%)
|
68(87.2%)
|
0.701
|
88(84.6%)
|
128(85.9%)
|
0.857
|
67(87.0%)
|
149(84.7%)
|
0.702
|
78(82.1%)
|
138(87.3%)
|
0.274
|
|
Female
|
27(18.2%)
|
10(12.8%)
| |
16(15.4%)
|
21(14.1%)
| |
10(13.0%)
|
27(15.3%)
| |
17(17.9%)
|
20(12.7%)
| |
|
Age (years)
|
|
≤ 47
|
88(50.3%)
|
45(57.7%)
|
0.340
|
49(47.1%)
|
84(56.4%)
|
0.161
|
42(54.5%)
|
91(51.7%)
|
0.684
|
50(52.6%)
|
83(52.5%)
|
> 0.999
|
|
> 47
|
87(49.7%)
|
33(42.3%)
| |
55(52.9%)
|
65(43.6%)
| |
35(45.5%)
|
85(48.3%)
| |
45(47.4%)
|
75(47.5%)
| |
|
T stage #
|
|
T1
|
10(5.7%)
|
2(2.6%)
|
0.089
|
7(6.7%)
|
5(3.4%)
|
0.187
|
4(5.2%)
|
8(4.5%)
|
0.984
|
5(5.3%)
|
7(4.4%)
|
0.008
|
|
T2
|
19(10.9%)
|
3(3.8%)
| |
7(6.7%)
|
15(10.1%)
| |
7(9.1%)
|
15(8.5%)
| |
15(15.8%)
|
7(4.4%)
| |
|
T3
|
93(53.1%)
|
40(51.3%)
| |
49(47.1%)
|
84(56.4%)
| |
39(50.6%)
|
94(53.4%)
| |
50(52.6%)
|
83(52.5%)
| |
|
T4
|
53(30.3%)
|
33(42.3%)
| |
41(39.4%)
|
45(30.2%)
| |
27(35.1%)
|
59(33.5%)
| |
25(26.3%)
|
61(38.6%)
| |
|
N stage #
|
|
N0
|
4(2.3%)
|
0(0.0%)
|
0.525*
|
4(3.8%)
|
0(0.0%)
|
< 0.001*
|
2(2.6%)
|
2(1.1%)
|
0.332*
|
4(4.2%)
|
0(0.0%)
|
0.002*
|
|
N1
|
21(12.0%)
|
7(9.0%)
| |
18(17.3%)
|
10(6.7%)
| |
8(10.4%)
|
20(11.4%)
| |
13(13.7%)
|
15(9.5%)
| |
|
N2
|
66(37.7%)
|
28(35.9%)
| |
42(40.4%)
|
52(34.9%)
| |
34(44.2%)
|
60(34.1%)
| |
42(44.2%)
|
52(32.9%)
| |
|
N3
|
84(48.0%)
|
43(55.1%)
| |
40(38.5%)
|
87(58.4%)
| |
33(42.9%)
|
94(53.4%)
| |
36(37.9%)
|
91(57.6%)
| |
|
Metastatic site sites
|
|
Bone
|
87(49.7%)
|
29(37.2%)
|
0.056
|
58(55.8%)
|
58(38.9%)
|
0.005
|
31(40.3%)
|
85(48.3%)
|
< 0.001
|
47(49.5%)
|
69(43.7%)
|
0.001
|
|
Lung
|
20(11.4%)
|
8(10.3%)
| |
13(12.5%)
|
15(10.1%)
| |
13(16.9%)
|
15(8.5%)
| |
17(17.9%)
|
11(7.0%)
| |
|
Liver
|
8(4.6%)
|
6(7.7%)
| |
5(4.8%)
|
9(6.0%)
| |
5(6.5%)
|
9(5.1%)
| |
5(5.3%)
|
9(5.7%)
| |
|
Distant nodes
|
18(10.3%)
|
4(5.1%)
| |
11(10.6%)
|
11(7.4%)
| |
15(19.5%)
|
7(4.0%)
| |
11(11.6%)
|
11(7.0%)
| |
|
Multiple sites
|
42(24.0%)
|
31(39.7%)
| |
17(16.3%)
|
56(37.6%)
| |
13(16.9%)
|
60(34.1%)
| |
15(15.8%)
|
58(36.7%)
| |
|
LRRT use
|
|
No
|
60(34.3%)
|
29(37.7%)
|
0.668
|
34(33.3%)
|
55(36.9%)
|
0.592
|
20(26.0%)
|
69(39.4%)
|
0.045
|
28(29.5%)
|
61(38.9%)
|
0.137
|
|
Yes
|
115(65.7%)
|
48(62.3%)
| |
69(67.0%)
|
94(63.1%)
| |
57(74.0%)
|
106(60.6%)
| |
67(70.5%)
|
96(61.1%)
| |
- Abbreviations: LRRT locoregional radiotherapy
- According to the 8th edition of the UICC/AJCC staging system
- The P value was calculated with the Pearson χ2 test or Fisher’s exact test (*)
- Bold data referred to statistical significance (P < 0.05)
